Eric Lefkofsky: Being Proud of His Company’s Financial Achievement for a Good Cause

Introduction

It was recently reported that a very worthy company was awarded an additional round of funding, thus putting them into a “unicorn” status. Named Tempus, this is a cancer-fighting firm that recently was awarded additional funding. And because of this, their value is now worth approximately $2billion dollars, according to the company’s co-founder and CEO, Eric Lefkofsky. Being over a billion dollars put them in an “unicorn” status, and not that many start-ups can claim they are worth over a billion dollars.

More About Tempus

Established a few years ago, Tempus was created when it was observed that the health care system was not using data that may have been valuable towards the treatment of patients suffering from cancer. This sort of situation really hit home when a loved one of Lefkofsky had been suffering from cancer.

Nevertheless, since this company’s inception, it has been making huge strides in using genomic data to better treat cancer patients. Located in Chicago, Illinois, Tempus has already grown significantly with the hiring of a bigger and stronger labor force to more aggressively work with enriched genomic data that goes a long way for cancer treatment. Before the last funding amount received which is around $80 million, they received around $70 million. In this case, they hired 400 employees, approximating around 30 more employees added monthly. And now they are planning on hiring even more labor force, especially in the data and tech fields at their company.

The Co-founder and CEO

Originally from a suburb outside of Detroit, Michigan, Lefkofsky is a serial entrepreneur and businessman. He began his entrepreneurship early on, and he also earned a bachelor of arts degree and a Juris Doctorate degree from the University of Michigan.

http://www.chicagobusiness.com/article/20161001/ISSUE01/310019995/can-eric-lefkofsky-save-your-life

Dr. David Samadi Support to Prostate Cancer

The now-former presidential nominee of the Republicans, Mitt Romney recently went through an operation to remove a slow-growing tumor in the prostate glands. Dr. Thomas Ahlering was able to undertake the surgery successfully eliminating cancer at UC Irvine Hospital. There many people who are diagnosed with cancer every year as Mitt joined the more than 150,000 people earlier in the year when diagnosed. Prostate cancer is not typical for the younger generation as men aged more than 65 years being the commonly affected. Romney had just turned 70 when cancer was detected. Romney is not the only politician to successfully go through a cancer operation successfully as the former secretary of state Colin Powell, and John Kerry has also undergone surgery to remove cancer. When an individual is discovered to have prostate cancer, there are two options for removing the tumor. One can decide to go through surgery or radiation. Dr. David Samadi who is an oncologist and urologist would give the pros and cons of both procedures so that an individual can make a rational decision.

Prostate cancer can occur in two forms when located in the prostate gland, or it has spread out of the organ. The first step that the physician takes is establishing the type of cancer that the patient is suffering from and its current stage. Physicians prefer the use of surgery compared to radiation as a method of treatment due to the less risk of surgery and higher level success. Dr. David Samada is the chairman of the Department of Urology and Chief of Robotic Surgery at Lenox Hill Medical Center. David Samadi is an expert when it comes to the diagnosis and therapy of prostate cancer, the cancer of the kidney, bladder cancer, and urologic disease. David is also a specialist in the persistent prostate cancer treatment through the implementation of radical prostatectomy. David left his home country Iran at the age 15 after the Iranian revolution. David continued his education in London and later Belgium before emigrating to the US where he completed high school. David Samadi then joined the University of Stony Brook earning an undergraduate degree in biochemistry.